Virtual Library
Start Your Search
J.R. Penrod
Author of
-
+
P2.03b - Poster Session with Presenters Present (ID 465)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-097 - Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (ID 4582)
14:30 - 14:30 | Author(s): J.R. Penrod
- Abstract
Background:
The LENS (Leading the Evaluation of Non-squamous and Squamous NSCLC) retrospective medical chart review was undertaken to describe characteristics, treatment patterns and outcomes among patients receiving systemic treatment for advanced/metastatic NSCLC in Europe. This analysis reports on prognostic factors associated with overall survival (OS) from start of first line treatment (1L).
Methods:
Patients with NSCLC stage IIIb/IV diagnosis between July 2009 and August 2011 were sampled from oncology/pulmonology practices in France, Germany, Italy, and Spain. Patients were followed to their most recent visit (data collected October 2013 to April 2014). Data were extracted from medical charts. Prognostic factors associated with OS from start of 1L were examined through Cox proportional hazard estimation. Independent clinically relevant variables included age, gender, tumor histology, and TNM disease stage. Additionally, variables for presence of metastases, prior administration of mutation (EGFR, ALK, KRAS) tests, surgery, and health insurance type were included. A backwards selection process (model 1) was applied to select the variables from the latter group with a significance level of 0.1. The remaining variables were entered into a second model 2 with all clinically relevant variables regardless of their significance. The final model 3 included all clinically relevant variables plus the significant variables from model 2.
Results:Significant Prognostic Factors for OS from Start of 1L (p<.05) in Final Multivariable Model
The analysis included data from 736 1L patients from 168 sites in the four countries, who were followed for a mean of 1.7 years (range: 22 days – 4.6 years) until the most recent visit (28.9%) or death (71.1%).Variable (Reference) Level Hazard Ratio (95%CI) P-Value Age Category at first diagnosis (<65 ) >79 2.6 (1.9-3.7) <.0001 Country (Germany) Spain 1.6 (1.2-2.0) <.0001 TNM disease stage (IIIB) IV 1.6 (1.2-2.1) <.0001 ECOG Score (0) 1 2+ 1.5 (1.2-1.9) 2.8 (2.1-3.7) <.0001 <.0001 Smoking (Never) Current Former 2.3 (1.7-3.2) 1.6 (1.2-2.1) <.0001 .005 Malignant Pleural Effusion (No) Yes 1.3 (1.0-1.5) .037 Any Mutation Testing Conducted (No) Yes 0.74 (0.6-0.91) .004 EGFR+ Mutation Test (Negative, Not Tested, Inconclusive) Yes 0.75 (0.6-0.97) .027 Surgery (No) Yes 0.36 (0.2-0.6) <.0001
Conclusion:
This rich multi-country clinical dataset provides insight into real world patient clinical, demographic, and treatment characteristics prognostic for OS. The results indicate survival worsened for patients who were older, with higher ECOG scores, TNM stage IV, and smokers. Prior surgery and EGFR testing were associated with improved survival. OS was not associated with insurance plan type.
